ChronoScale Holdings Corporation disclosed that Scott Davis, a member of its Board and CEO of Ekso Bionics, Inc., resigned from the Board effective October 3, 2026, following the September 30, 2026 sale of Ekso. The company stated that there were no disagreements with Davis leading to his resignation.
On October 2, 2026, ChronoScale granted Davis 51,626 restricted stock units, which fully vested that day, and entered into a Release Agreement providing for a $709,500 lump-sum cash payment, less applicable withholdings and deductions. The payment is subject to Davis’s compliance with the agreement and his continuing restrictive covenants, and is payable within 30 days of execution. The agreement is in lieu of and in full satisfaction of any payment or benefit under a Change in Control and Severance Agreement; it does not amend the separate Phantom Performance-Based Restricted Stock Unit Agreement.
ChronoScale Holdings Corporation may offer securities under a shelf registration with an aggregate public offering price of up to $500,000,000, in one or more offerings. The securities may include non-convertible preferred stock, debt securities and junior subordinated debt securities. Selling securityholders may also offer securities in amounts set out in a prospectus supplement. Unless the applicable prospectus supplement or free writing prospectus provides otherwise, ChronoScale expects to use net proceeds from its own offerings for working capital and general corporate purposes.
ChronoScale provides cloud services through ChronoScale Corporation at third-party colocation centers. A two-year strategic partnership with Microsoft, entered into August 6, 2026, supports a planned deployment of approximately 50 megawatts of AI compute capacity, expected to be completed in the first calendar quarter of 2027. The deployment is subject to financing on favorable terms and other customary development, construction and operational conditions and milestones; penalties and other credits could be available to the counterparty if ChronoScale does not meet or perform them.
ChronoScale Holdings Corp (symbol: CHRN) is the issuer of record for a Form 8-K filing submitted to the SEC.
ChronoScale Holdings Corporation (CHRN) is seeking stockholder votes at its November 6, 2026 virtual annual meeting on eight director nominees, auditor ratification for the fiscal year ending May 31, 2027, an advisory vote on named executive compensation, ratification of certain non-employee director restricted stock awards, and possible adjournment. As of September 10, 2026, 145,637,452 common shares were outstanding, with one vote per share.
ChronoScale completed a holding company restructuring on July 1, 2026, making ChronoScale Holdings the public parent of its Cloud Business and Legacy Ekso Business. The board committed on May 29, 2026, to a plan to divest Legacy Ekso and focus future operations solely on Cloud; the company expects to complete the divestiture during fiscal year 2027. Legacy Ekso is classified as held for sale and discontinued operations in the consolidated audited financial statements.
Rajasekar Jegannathan, Chief Technology Officer, notified the company on September 18, 2026, of his intention to resign effective October 2, 2026.
ChronoScale Holdings Corporation (CHRN) is soliciting stockholder votes for its virtual annual meeting on November 6, 2026, where holders of common stock as of September 10, 2026 (145,637,452 shares outstanding) will elect eight directors and act on four additional governance and compensation proposals. These include ratifying CBIZ CPAs P.C. as auditor, an advisory say-on-pay vote, ratifying restricted stock awards to non-employee directors under the 2026 Plan, and approving potential adjournment of the meeting if more time is needed to secure votes.
The company explains its 2026 holding company reorganization, under which ChronoScale Holdings became the public parent over two segments: the cloud infrastructure business operated through ChronoScale Corporation and the Legacy Ekso exoskeleton business, which the board committed on May 29, 2026 to divest and has classified as held for sale and discontinued operations. Although more than 50% of voting power is held by an Applied Digital affiliate, the board has chosen not to rely on most “controlled company” exemptions and has formed fully independent audit, compensation, nominating, and related-party transaction committees. The proxy also details refreshed board composition and key executive arrangements, including CEO Ying Cenly Chen’s $650,000 base salary and 2.8 million RSU grant and updated severance and RSU terms for CFO Jerome Wong.
ChronoScale Holdings Corporation (CHRN) reports that its wholly owned subsidiary ChronoScale Intermediate, LLC, as borrower, and Ekso Bionics, Inc., as guarantor, entered into a First Amendment to their Secured Promissory Note and Security Agreement with B. Riley Commercial Capital, LLC.
The underlying term loan has an aggregate principal amount of up to $2.0 million, all of which was outstanding as of the amendment date. The amendment extends the loan’s time-based maturity to November 12, 2026 and specifies that a sale of the guarantor on the terms described in the amendment will be treated as a Permitted Disposition. All other material terms of the original agreement remain in effect.
ChronoScale Holdings Corporation (CHRN) has called a virtual annual stockholders meeting for November 6, 2026, to vote on electing eight directors, ratifying CBIZ CPAs P.C. as auditor for the fiscal year ending May 31, 2027, an advisory vote on executive pay, ratification of restricted stock awards to non‑employee directors, and a possible adjournment if more time is needed to solicit votes.
ChronoScale operates two businesses through wholly owned subsidiaries: a cloud services business providing infrastructure for artificial intelligence and machine learning customers at colocation centers in Colorado, Minnesota and Utah, and the Legacy Ekso exoskeleton business, which the board committed on May 29, 2026 to divest, with completion expected during fiscal 2027 and financial reporting as held for sale and discontinued operations.
The proxy describes a 2026 holding‑company restructuring that made ChronoScale Holdings the public parent and successor issuer, outlines a majority‑independent eight‑member board with audit, compensation, nominating and related‑party committees, and details executive compensation and new employment arrangements, including time‑vested restricted stock unit grants and severance protections for senior management.
ChronoScale Holdings Corporation (CHRN) reported that it has entered into a strategic AI infrastructure partnership with Microsoft for a planned 50-megawatt (MW) AI compute deployment in North America. The deployment is expected to use NVIDIA GB300 NVL72 systems with advanced liquid-cooling, high-performance networking, storage, and purpose-built data center infrastructure to support large-scale AI training and inference workloads.
The company also disclosed that the term of its previously announced strategic partnership with Microsoft has been extended from two years to three years, reflecting a longer planned collaboration around this AI compute deployment. ChronoScale positions its platform as an accelerated compute environment purpose-built for demanding AI workloads and emphasizes that numerous risks and uncertainties, including integration of its recently completed business combination, capital access, and cloud compute industry growth, could affect actual outcomes versus current expectations.
ChronoScale Holdings Corp (CHRN) filed its annual report outlining a major transformation into a focused AI cloud infrastructure provider. The company now operates primarily through its Cloud Business, which rents GPU capacity in third-party colocation centers in Colorado, Minnesota, and Utah and serves high-performance AI and machine learning workloads.
Cloud services, delivered via 6,144 deployed NVIDIA H100 GPUs and about 14 MW of colocation capacity, generated approximately 99.5% of total revenue for the year ended May 31, 2026, but currently come from a single customer, Together AI, under a 12‑month contract that auto‑renews in 60‑day increments. The legacy Ekso exoskeleton segment is classified as held for sale and reported as discontinued operations, with divestiture expected in fiscal 2027.
ChronoScale reported consolidated net losses of $50.3 million in fiscal 2026 and $72.7 million in 2025 and expects to raise additional capital, implying future dilution. The company highlights growth initiatives including a two‑year strategic partnership with Microsoft to support roughly 50 MW of new AI compute, a strategic partnership with Nutanix, and an expanded platform roadmap (NeoCloud infrastructure, GPU‑as‑a‑Service, Token Factory, and ChronoScale Foundry). Key risks include customer and supplier concentration, financing needs, execution risk on large deployments, potential penalties if Microsoft milestones are missed, heavy regulation around AI infrastructure, and dependence on Applied Digital as a controlling shareholder.